We are pleased to announce that this week, we are officially launching our 177Lu-octreotate PRRT clinical trial at CHU de Québec, which is called:
Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study
Our trial is unique in that we will administer personalized doses of 177Lu-octreotate to maximize tumour irradiation, while limiting irradiation of healthy organs. We believe that this approach will improve the efficacy of 177Lu PRRT, without increasing its toxicity.
At present, we have the capacity to treat out-of-province patients (through formal referral by their physician). Any enquiries can be directed to me.
Regards,
Dr. Jean-Mathieu Beauregard
Assistant Professor
Dept. of Radiology and Nuclear Medicine
Université Laval